Original title:&nbsp;Renal Function-Based Contrast Dosing Predicts Acute Kidney Following Trancatheter Aortic Valve Implantation&nbsp;Reference:&nbsp;Masanori Yamamoto, et al. J Am Coll Cardiol Intv 2013;6:479&ndash;86. Acute kidney injury (AKI) presents in 10 to 30% of patients undergoing TAVI; it is associated to the increase of morbidity and mortality and it prolongues hospitalization. This study included 415 patients with<a href="https://solaci.org/en/2013/06/05/what-is-the-contrast-media-dosing-that-predicts-acute-kidney-injury-after-tavi/" title="Read more" >...</a>

Original title:&nbsp;Post-Procedural Hypertension Following Transcatheter Aortic Valve Implantation Incidence and Clinical Significance.&nbsp;Reference:&nbsp;Gidon Y. Perlman et al. J Am Coll Cardiol Intv 2013. Article in press. Pre-procedural hypertension (HTN) is a risk factor and a predictor of increased mortality after surgical aortic valve replacement (AVR). The disappearance of the pressure gradient across the aortic valve following<a href="https://solaci.org/en/2013/05/02/post-tavi-hypertension-is-a-predictor-of-better-evolution/" title="Read more" >...</a>

Original title:&nbsp;5 Years Experience With Trancatheter Tranaspical Mitral Valve &ndash;in Valve Implantation for Bioprosthetic Valve Dysfunction&nbsp;Reference:&nbsp;Anson Cheung et al. J Am Coll Cardiol 2013;61:1759&ndash;66. Percutaneous valves development, first aortic and now mitral, has brought an opportunity to improve life quality and extend life for high risk non-surgical patients. 23 patients received transapical implantation in mitral<a href="https://solaci.org/en/2013/04/29/valve-in-valve-implantation-is-possible/" title="Read more" >...</a>

Original title:&nbsp;5-Year Outcome After Aortic Valve Implantation&nbsp;Reference:&nbsp;Stefan Toggweiler, et al. J Am Coll Cardiol 2013;61:413&ndash;9 Percutaneous aortic valve implantation (TAVI) is now a valid strategy as we know its short and medium term evolution but we do not have enough information available about the long term.&nbsp; The aim of this study was to analyze the<a href="https://solaci.org/en/2013/01/28/favorable-outcomes-at-5-years-post-tavi/" title="Read more" >...</a>

Original title: Valve-in-Valve Implantation of Medtronic CoreValve Prosthesis in Patients with Failing Bioprosthetic Aortic Valves. Reference: Axel Linke el al. Circ Cardiovasc Interv. 2012;5:689-697. This study evaluates the safety, feasibility and results of Core Valve implants on patients with bioprostheses dysfunctional by stenosis, insufficiency or a combination of both. Biological prostheses are preferred over mechanical ones for patients<a href="https://solaci.org/en/2012/11/02/the-largest-published-series-of-valve-in-valve-with-core-valve-medtronic/" title="Read more" >...</a>

Reference:&nbsp;G&eacute;n&eacute;reux, et al, for the PARTNER Trial Investigators. JACC 2012; 60 (12):1043-62 Original title: Vascular complications after Transcatheter Aortic Valve Replacement: Insights From the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial The purpose of the study was to investigate the incidence, predictors and vascular complications impact after catheter aortic valve implantation (TAVI) in the PARTNER<a href="https://solaci.org/en/2012/10/01/vascular-complications-after-valvular-replacement-using-catheter-partner-trial-findings/" title="Read more" >...</a>

Reference: Sinning et al. AHJ Am Heart J 2012;164:102-110 Percutaneous aortic valve replacement (TAVI) is a novel technique for the treatment of severe aortic stenosis (SAS) that has been built with great enthusiasm in clinical practice, particularly in patients with excessive surgical risk. In these patients, a high obstructive peripheral vascular disease stands, a fact<a href="https://solaci.org/en/2012/10/01/tavi-more-risky-in-patients-with-peripheral-vascular-disease/" title="Read more" >...</a>